Roche pushes a novel myeloma target
The company will be the first to take a FcRH5-targeting project into phase 3.
Roche sets up a breast cancer déjà vu
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
What now for NK-cell engagers?
Big pharma interest remains, but the mood is fast turning gloomy.
Kura harks back to its roots
After menin, the company tries again with farnesyl transferase.
Revolution could have a first-line pancreatic balancing act
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
Rezatopopt sees a path forward after all
Pivotal data set the stage for slightly delayed US accelerated approval filing.
